Is this your company? Get featured or correct your listing →
Company Snapshot
Encore Medical is a Medical devices company, based in Eagan, Minnesota, USA, founded 2017 by Joseph A. Marino.
Recent changes
- Sep 5, 2026Sep 5, 2026First reported valuation: ~$53.72M (projected)Estimated stockanalysis.com
- Jul 1, 2026Jul 1, 2026IPO 3,000,000 shares at ~$5.00/share (~$12.6M-$15M target)Rumored SEC EDGAR
- Jul 1, 2026Jul 1, 2026Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device Pulse story
- Jun 30, 2026Jun 30, 2026Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 2026 | IPORumored | 3,000,000 shares at ~$5.00/share (~$12.6M-$15M target) | — | SEC EDGAR |
Latest Pulse
- Jul 1, 2026Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure DeviceEncore Medical filed an amended S-1 on July 1 ahead of a planned NYSE American listing under ticker EMI, offering 3 million shares at an expected $5.00 each to raise roughly $12.6-14.67 million to fund US clinical trials for its catheter-delivered heart-defect closure device, which has completed more than 35,000 implants outside the United States but has not yet been approved for US sale. Underwriters BofA Securities, Goldman Sachs and Morgan Stanley are jointly leading the offering.→
- Jun 30, 2026Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway TightensEncore Medical, a structural heart device company developing transcatheter septal occlusion products, filed its latest S-1/A on June 30, targeting an IPO of 3 million shares at an expected $5 per share on NYSE American under ticker EMI. The company's cash balance stood at just $34,619 as of March 31, 2026, underscoring how urgently it needs the offering to fund ongoing US clinical trials.→
Coverage Timeline
newest firstAll Coverage
IPO~$12.6M-$14.67M
Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device
Encore Medical filed an amended S-1 on July 1 ahead of a planned NYSE American listing under ticker EMI, offering 3 million shares at an expected $5.00 each to raise roughly $12.6-14.67 million to fund US clinical trials for its catheter-delivered heart-defect closure device, which has completed more than 35,000 implants outside the United States but has not yet been approved for US sale. Underwriters BofA Securities, Goldman Sachs and Morgan Stanley are jointly leading the offering.
Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens
IPO$5.00/share IPO
Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens
Encore Medical, a structural heart device company developing transcatheter septal occlusion products, filed its latest S-1/A on June 30, targeting an IPO of 3 million shares at an expected $5 per share on NYSE American under ticker EMI. The company's cash balance stood at just $34,619 as of March 31, 2026, underscoring how urgently it needs the offering to fund ongoing US clinical trials.
Encore Medical FAQ
Is Encore Medical publicly traded?
Yes. Encore Medical trades under the ticker EMI.
Sources & methodologyshow
Where these figures come from
- SEC EDGARprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.